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Abstract
Background: In order to develop a new immunotherapeutic agent targeting metastatic breast cancers, we chose
to utilize autocatalytic feature of the membrane serine protease Prss14/ST14, a specific prognosis marker for ER
negative breast cancer as a target molecule.
Methods: The study was conducted using three mouse breast cancer models, 4 T1 and E0771 mouse breast cancer
cells into their syngeneic hosts, and an MMTV-PyMT transgenic mouse strain was used. Prss14/ST14 knockdown
cells were used to test function in tumor growth and metastasis, peptides derived from the autocatalytic loop for
activation were tested as preventive metastasis vaccine, and monoclonal and humanized antibodies to the same
epitope were tested as new therapeutic candidates. ELISA, immunoprecipitation, Immunofluorescent staining, and
flow cytometry were used to examine antigen binding. The functions of antibodies were tested in vitro for cell
migration and in vivo for tumor growth and metastasis.
Results: Prss14/ST14 is critically involved in the metastasis of breast cancer and poor survival rather than
primary tumor growth in two mouse models. The epitopes derived from the specific autocatalytic loop region
of Prss14/ST14, based on structural modeling acted as efficient preventive metastasis vaccines in mice. A new
specific monoclonal antibody mAb3F3 generated against the engineered loop structure could reduce cell
migration, eliminate metastasis in PyMT mice, and can detect the Prss14/ST14 protein expressed in various
human cancer cells. Humanized antibody huAb3F3 maintained the specificity and reduced the migration of
human breast cancer cells in vitro.
Conclusion: Our study demonstrates that Prss14/ST14 is an important target for modulating metastasis. Our
newly developed hybridoma mAbs and humanized antibody can be further developed as new promising
candidates for the use in diagnosis and in immunotherapy of human metastatic breast cancer.
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Background
Prss14 (serine protease 14)/ST14 (suppression of
tumorigenicity 14), also known as epithin [1], matriptase
[2], and membrane-type serine protease 1 (MT-SP1) [3],
is the representative member of type II transmembrane
serine proteases [4–6].
Multiple pathologic analyses of cancer patients’ samples
showed that over-expression of Prss14/ST14 is consist-
ently found in progressed cancers of epithelial types
(reviewed in [5, 7]). Our careful examination on post sur-
gery esophageal squamous cell carcinoma patients showed
that the prognosis of disease free survival is extremely
poor with Prss14/ST14 expression [8]. Its high level of ex-
pression was detected in various human breast cancer cell
lines [9, 10] and breast cancer tissues [11–14]. The im-
portance of Prss14/ST14 in breast cancer progression, me-
tastasis, and patient’s survival is now clear. Recently, we
reported that Prss14/ST14 is an excellent prognostic
marker for estrogen receptor negative (ER−) or triple
negative (TN) breast cancer type after systemically analyz-
ing the signature genes of breast cancer types (ER, PR,
HER2) and the epidermal-mesenchymal transition (EMT)
genes using public gene expression data bases [8].
There are multiple genetically modified mouse models
that exhibit phenotypes of Prss14/ST14 associated can-
cer. When the K5 promoter is used in transgenic expres-
sion of Prss14/ST14, mice spontaneously develop skin
adenoma that can be accelerated by tumor promoting
chemicals [15]. This study showed clear oncogenic func-
tion of Prss14/ST14. When MMTV-PyMT mouse
models crossed with the matriptase hypomorphic mouse
model [16], animals showed less breast cancer tumor
burden and lived longer than the ones with normal
levels of Prss14/ST14 expression [17]. This study also
showed that Prss14/ST14 plays a critical role in cMet
signaling in response to HGF secreted from the fibro-
blast in the tumor microenvironment.
The cellular functions of Prss14/ST14 for cancer progres-
sion and metastasis have been studied extensively using
Prss14/ST14 high expressing cells and mouse models. 1)
Ectodomain shed from the cell into culture media induced
angiogenesis, such as endothelial cell migration, invasion
and tube formation [18]. This angiogenic process can be
blocked by specific polyclonal antibodies. 2) Prss14/ST14 is
necessary and sufficient for EMT [19]. TGFβ induced EMT
in the thymoma cell line 427.1.86 was blocked when
Prss14/ST14 message was knocked down. In addition, when
Prss14/ST14 gene expression was introduced, it led to EMT
in MDCK cells. 3) Prss14/ST14 is critically involved in
transendothelial cell migration of cancer cells via the upreg-
ulation of Tie2 signaling in the endothelium [20], and of
macrophages upon IFNγ activation [21]. 4) Prss14/ST14 is
important for 4 T1 breast cancer cells to form lung metasta-
sis nodules in the intravenous tail vein injection model [20].
Many known specific substrates for Prss14/ST14 prote-
ase are well known for their roles in tumor progression
and metastasis and can be categorized into multiple fam-
ilies [5, 7]. Extracellular matrix proteins including collagen
and fibronectin can be degraded by the Prss14/ST14 pro-
tease activity. Therefore, the basement membrane is modi-
fied for easy cell infiltration during metastasis. Proteins
involved in the tumor growth and proliferation such as
EGFR [22] and PDGF-D [23, 24] are also the known sub-
strates. Another family of proteins, such as MSP-1 [25]
and Laminin 322 [26], are involved in cellular survival. In
addition, Prss14/ST14 protease can activate multiple pro-
tease cascades by cleaving PAR-2 [27–29], uPA [9, 30],
and MMP3 [31]. Prss14/ST14 protease activity can induce
signaling by cleaving and activating either the cellular re-
ceptors or the ligands [7]. The capacity of auto activation
of this protease [32, 33] is a key feature as an important
part of the regulatory target to block tumor progression
and metastasis.
In this report, we show that Prss14/ST14 is critically
involved in lung metastasis of mouse breast cancer, and
that an epitope containing the autocatalytic loop portion
of the Prss14/ST14 protein can function as a preventive
metastasis vaccine. A new monoclonal antibody specific
for the autocatalytic loop recognizes the epitope in se-
quence and structure specific fashion and can reduce




MCF7, T47D, MDA-MB-453, SNU216, MKN45, PC3,
OE19, and HCT116 human cell lines were obtained from
Dongeun Park (Seoul National University) and Jung Hwa
Kim (Inha University). All cells were maintained in Dulbec-
co’s Modified Eagle’s Media (DMEM; Welgene) supple-
mented with 10% fetal bovine serum (FBS; Welgene or
Gibco), penicillin and streptomycin (Welgene), and 4mM
L-glutamine (Welgene). All adherent cells were subcultured
every 2~3 days with trypsin-EDTA (Welgene). Balb/c and
C57BL/6 mice were purchased from Daehan Biolink. Mice
were maintained in the Laboratory of Molecular and Cellu-
lar Immunology Animal Facility at Inha University and
Korea Bio in Korea University in compliance with the use
of Laboratory Animals under proper protocols. For ortho-
topic mouse breast cancer models, female Balb/c mice for
4 T1 cells or C57BL/6 for E0771 cells were anesthetized
with Avertin (2,2,2-Tribromoethanol (Sigma) in 2-Methyl-
butanol-2 (Sigma)). The incision was closed with wound
clips and the primary tumor outgrowth was monitored
twice a week by taking measurements of the tumor length
(a) and width (b). Tumor volume (V) was calculated by
the formula determined by Carlsson: V = (ab2)/2, where ‘a’
and ‘b’ are the longest and shortest diameters of the tumor
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respectively [34]. For the antibody effect on the tumor
model, female MMTV-PyMT mice at the age of 9 weeks
old were intraperitoneally injected with PBS, Taxol, or
mAb3F3 antibody with amounts at 50 μg/mouse. Treat-
ment of five mice per group was initiated at 9 weeks old
and injections were performed twice a week until 14
weeks of age. Tumor size was measured twice a week.
Mice were euthanized at 15 weeks of age. The number
and areas of nodules in the lung were measured by using
ImageJ following photography.
Antigenic peptide synthesis
Peptides were synthesized by Thermo or Abclone. The
formation of a disulfide bond between the both ends was
assessed via mass spectrometry (Abclone). Conjugation
to keyhole limpet hemocyanin (KLH) or bovine serum
albumin (BSA) was performed by Young In Frontier.
Epi-Sc (EQGKGARDWPEWAVQGVNT), which has the
same amino acid composition as the Epi-SP peptide
(KQARVVGGTNADEGEWPWQ), was chosen using the
web site (http://users.umassmed.edu/ian.york/Scramble.
shtml) and synthesized by Young In Frontier.
Protein structure modeling
The tertiary model structures of proteins and peptides were
obtained from I-TASSER server (http://zhanglab.ccmb.
med.unich.edu/I-TASSER/). The predicted models were
analyzed by Chimera software (htt://www.cgl.ucsf.edu/
chimera/download.html). Structure modeling of fragment
antigen-binding (Fab) of the monoclonal antibody was per-
formed by using PIGS web server (http://www.biocomput-
ing.it/pigs). Antigen-Antibody docking modeling was
obtained by ClusPro 2.0 web server (htt://cluspro.bu.edu).
In vitro cell migration assays
For the wound healing migration assay, cells were grown
to confluence. A linear mechanical scratch wound was
generated using a blue tip. Cells were then incubated in
low serum media. The wounded areas were observed
under a microscope (IX51, Olympus). The samples were
analyzed by wound healing tool in ImageJ software. For
testing the antiserum in transendothelial migration
assay, MS1 cells (5 X 104) were grown on Boyden Cham-
ber (8 μm pore insert, Falcon) until they reached to con-
fluency. The 4 T1 cells were stained with CFSE
(Molecular Probes) and resuspended with DMEM con-
taining 5% FBS and anti-Epi-SP sera. The CFSE-stained
1 X 105 4 T1 cells were added onto the MS1 cells and
incubated for 4 h. Cells were fixed with 3.7% formalde-
hyde, and remaining cells were scrubbed and washed.
Images of CFSE-positive cells that migrated to the op-
posite side were obtained by using a microscope (IX51,
Olympus) with AxioCam MRm (Zeiss). For testing puri-
fied antibodies, transwell migration assay was performed
using Boyden Chamber. MCF7 cells (5 × 104) were
seeded on the upper chamber and incubated with anti-
body in serum-free media for 4 h. Then, the lower cham-
ber was filled with 10% serum-containing media. After
24 h of incubation, the cells on the upper surface of the
membrane were removed using cotton swabs. The cells
on the lower surface of the membrane were fixed with
100% methanol for 10 min and stained with 0.2% crystal
violet for 5 min. The migrated cells in ten fields from
triplicate experiments were counted.
Generation and humanization monoclonal antibody
Female Balb/c mice were immunized with a circular pep-
tide conjugated with KLH, in ImjectR Alum (Thermo) four
times at 3 week intervals. Three days before fusion, primed
mice were boosted with the final immunization. At the
day of fusion, a single-cell suspension from the harvested
spleen was fused with SP2/0-Ag14 myeloma with 50%
Polyethylene glycol (PEG) solution (Sigma) and plated in
96well plates with DMEM containing 20% serum. Hybrid-
oma cells were selected in Hypoxanthine, Aminopterin,
and Thymidine (HAT supplement) (Gibco) and main-
tained in Hypoxanthine and Thymidine (HT supplement)
(Gibco). Hybridoma clones were selected by limiting dilu-
tion twice. For humanization, hybidoma originated anti-
body was humanized using a CDR-grafting method. The
VH and VL sequences were searched for against the hu-
man germline sequence databases with IgBLAST (http://
www.ncbi.nlm.nih.gov/igblast/) and IMGT/V-QUEST
(http://www.imgt.org/IMGT_vquest/share/textes/), and
the most similar human germ line Fv sequence and J re-
gion were identified. The residues within combined
KABAT/IMGT CDR regions were grafted onto the frame-
work regions of templates.
Surface Plasmon resonance (SPR)
Binding of antibodies to the BSA conjugated peptide anti-
gens were assayed using a Biacore T200 instrument (GE
healthcare). Antibodies were injected for 60 s using a flow
rate of 10 μl/min in the active flow cell only. For kinetic
studies, antigens were diluted to the ranges of 1.25 to 20
nM. Signal detection was at a rate of 10 signals per sec-
ond. Binding constants were determined using BIA Evalu-
ation software version 1.0 (GE Healthcare).
Enzyme-linked immunosorbent assay (ELISA)
For conventional ELISA, 50 ng of peptides in coating buffer
(32mM Na2CO3, 68mM NaHCO3, 0.1% NaN3, pH 9.6)
were coated on 96 well immunoplates (SPL), and blocked
with 1% nonfat dry milk in PBS. After washing with 0.4M
Tris-Buffered Saline (pH 7.4) containing 0.1% Tween20,
primary antibodies were added and incubated for 1 h at
37 °C. After washing, anti-mouse horseradish peroxidase
(HRP) conjugated antibody was added and incubated for 1
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h at 37 °C. Super AquaBlue ELISA substrate (eBioscience)
was used for measuring optical density at 405 nm using
ELISA Reader (TECAN, Sunrise™). Specific C-terminal
coating ELISA was performed with peptide coating kit from
TaKaRa by following the protocol provided. In the 96-well
reaction plate, 225 ng of peptides in reaction buffer were
coated with coupling reagent for 2 h at 37 °C. The coated
wells were blocked for 1 h. Rest of the process was the same
as for conventional ELISA except using distilled water as
the wash buffer.
Flow cytometry
To test mAb binding to native protein, HEK293T cells
transfected with constructs (full length human Prss14/
ST14, S805A mutant, and EGFP-S805A) were washed
with PBS twice and treated with Enzyme-Free PBS-based
cell dissociation buffer (Gibco) for single cell suspension.
When CHO-S cells and HEK293TF cells were used, cells
were harvested without dissociation. For analysis of
mouse mAb3F3, 5 × 105 CHO-S cells were used in FACS
buffer (0.1 mg/ml BSA in PBS). To detect live cells, Fix-
able Viability dye eFluor 455UV (affymetrix) was treated
for 30 min at 4 °C in dark. For cytoplasmic staining, cells
were fixed and permeabilized with Fix & Perm kit (CAL-
TAG) after washing. Human Fc receptor binding inhibi-
tor (affymetrix) was used to block Fc receptors. mAbs
were used as the primary antibody, PE conjugated anti-
mouse Kappa (PharMingen) was used as a secondary
antibody. Samples were filtered through 200 μm nylon
mesh and read using FACSCalibur (BD) and analyzed
using FlowJo software. For the analysis of humanized
antibodies, HEK293TF cells were incubated for 3 days
after co-transfection of pcDNA3.1/EGFP and
pcDNA3.1/matriptase(S805A)-TST or of pcDNA3.1 and
pCMV-tdTomato. The cells were washed with Free-
Style™ 293 Expression Medium. After blocking Fc recep-
tors with blocking buffer (10% normal hamster serum,
10% normal rat serum, anti-FcR mAb2.4G2) for 5 min,
the cells were fixed and permeabilized using Foxp3/
Transcription Factor Staining Buffer Set (ThermoFisher)
and stained with 30 μg/ml of humanized mAb3F3 anti-
body clones for 20 min. Alexa Fluor® 647 anti-human
IgG Fc antibody (BioLegend) were incubated for 15 min
for the secondary reagent. The samples were washed
with media before reading using BD Accuri™ Flow Cyt-
ometer, and analyzed using Flowjo 10.
Immunoprecipitation and western blotting
The cell lysates in IP buffer (150 mM NaCl, 1% Nonidet
P-40, 1 mM EDTA, 50 mM HEPES, pH 7.4 and protease
inhibitor cocktail) reacted with monoclonal antibodies
overnight at 4 °C on a rotator and reacted to 50% slurry
of protein A/G agarose bead (Pierce) for 2 h at room
temperature on a rotator. The protein A/G beads
capturing antibody-antigen complex were washed 3
times with PBS then mixed with SDS sample buffer and
incubated for 5 min at 99 °C. The eluted supernatant was
analyzed by western blot using PVDF membrane (Pall,
FluoroTrans). After the membranes were incubated with
5% skim milk in 0.1% TritonX-100 in PBS (PBS-T), and
reacted to polyclonal rabbit antibody IM1014 (Calbio-
chem) for human protein or polyclonal rabbit anti-
epithin serum [35] for mouse protein. HRP-conjugated
anti-rabbit IgG (1:5000 diluted) was used with Luminol/
Enhancer solution and Stable Peroxide solution (Super-
SignalR West Pico, Thermo). The chemiluminescence
was observed using LAS-4000mini (GE healthcare Life
Sciences) and signals of each band were digitized by
ImageJ.
Immunofluorescence
MCF7, T47D, MDA-MB-453, SNU216, MKN45, PC3,
OE19, HCT116, 427.1.86, and 4 T1 cells were seeded
onto chamber slide or 0.1% gelatin coated coverslip, and
fixed with 4% paraformaldehyde at room temperature
for 10 min. Then the cells were permeabilized with 0.5%
PBS-T and nonspecific binding was blocked with 10%
goat serum/1% gelatin in 0.1% PBS-T for 30min.
mAb3F3 were used as primary antibodies. FITC-conju-
gated anti-mouse IgG was used as secondary antibody.
Actin was visualized using phalloidin-iFluor647 (Abcam)
and nucleus was stained with 0.3 μM DAPI (Molecular
Probes) diluted in Mowiol mounting media (Sigma).
These stained cells were visualized using confocal micro-
scope LSM510 meta (Zeiss) and processed in Photoshop.
Cell proliferation assay
For measuring proliferation of cells, 5 × 104 of MCF7
cells were seeded in 12 well plates. The number of cells
was counted at every 24 h using LUNA-FL™ Fluores-
cence Cell Counter (Logos). Acridine Orange and Propi-
dium Iodide (Logos) were used to separate viable and
dead cells.
Cell cycle analysis
MCF7 cells were resuspended in 1.2 ml PBS and added
3ml ice cold 95% ethanol dropwise while vortexing to
fix the cells. The 1 × 106 fixed cells were treated with
RNase (100 μl/ml) and 400 μl Propidium Iodide (50 μg/
ml) for 30 min at room temperature. The samples were
read by FACSCalibur and analyzed by FlowJo.
Results
Prss14 is critical in metastasis of 4 T1 and E0771 mouse
breast cancer cells
In order to assess the role of Prss14/ST14 on the breast
cancer progression and metastasis, we used two mouse
breast cancer cell lines, highly metastatic 4 T1 and less
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metastatic E0771, and their syngeneic mouse hosts, Balb/c
and C57BL/6 strains, respectively (Fig.1). Prss14/ST14
knock down cells (EpiKD) and their control partner cells
(Con) were orthotopically injected into mammary fat pads,
and followed by the analysis of survival, tumor onset,
growth of the primary tumor, and metastasis to the lung.
The 4 T1 EpiKD [20] increased the survival in a dose
dependent fashion (Fig. 1a) while slightly decreased in the
growth rate of the primary tumor (Fig. 1b and c). Also, 4
T1 EpiKD significantly reduced the numbers of metastatic
nodules in the lung in comparison to the orthotopically
injected 4 T1 cells (Fig. 1c). Newly generated cell line
A B C
D E F
Fig. 1 Prss14/ST14 is critical for metastasis of orthotopically-implanted 4 T1 and E0771 breast cancer cells. (a) Survival curves of host mice
orthotopically injected with 4 T1 and 4 T1EpiKD cells. 1 × 102, 1 × 103, 1 × 104, 1 × 105, or 1 × 106 of 4 T1 control (Con; solid lines) or 4 T1EpiKD
(EpiKD; dotted lines) cells were implanted into the mammary fat pad of Balb/c mice. The cell numbers are indicated in the graph. (b) The growth
curves of 4 T1Con and 4 T1EpiKD primary tumors. From top to bottom, 1 × 104, 1 × 105, and 1 × 106 cells. (c) The weight of 4 T1 primary tumor
and the numbers of 4 T1 lung metastatic nodules. Upper panels: primary tumor weight, lower panels: nodule numbers. Filled circle: 4 T1Con,
empty circle: 4 T1EpiKD. Means and standard errors are indicated. (d) Survival rate of C57BL/6 mice implanted with E0771-Control-D11 (E0771Con,
solid line) or E0771-EpiKD-C3 (E0771EpiKD, dotted line) cells (1 × 104, 1 × 105, 1 × 106 cells/mouse (n = 10)). (e) The growth curves of E0771Con
and E0771EpiKD primary tumors. (f) Comparison of the E0771 primary tumor weight and E0771 lung weight. Filled circle: E0771Con, empty circle:
E0771EpiKD. P values measured by unpaired t test are shown
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E0771 EpiKD (Additional file 1: Figure S1) was used for
the same kind of experiments (Fig.1d-f). Knock down of
the Prss14/ST14 message in E0771 also slightly increased
the survival rate (Fig. 1d). Tumor growth (Fig. 1e and f)
and metastasis indicated the decreasing trend in lung
weight (Fig. 1f), but the statistical significances were much
lower than those for the results of 4 T1 EpiKD. In the case
of 4 T1 breast cancer model, which shows greater meta-
static nature than E0771, the metastasis of 4 T1 to the
lung is also clearly suppressed by the knockdown. These
results suggested that the Prss14/ST14 is required for effi-
cient 4 T1 tumor progression and metastasis.
Immunization of Prss14/ST14 antigenic peptides is
effective in abrogating metastasis of 4 T1 breast cancer
Since Prss14/ST14 plays the critical role of activating mul-
tiple downstream substrates, we made an assumption that
inhibiting function with antibodies can block tumor me-
tastasis and increase survival of tumor patients. Therefore,
we decided to design the antigenic epitopes that reveal
high antigenicity, hydrophilicity, surface probability, evolu-
tionary conservation, and avoided the area of protein
modification such as glycosylation. The most interesting
candidate initially selected from the region was the activa-
tion loop of the protease domain Epi-SP (19mer) (Fig. 2a).
This sequence includes the activation cleavage site
(QARVVG) and is highly conserved between mouse and
human (Fig. 2b). These epitopes are located in the appro-
priate positions to be antigens in the models (Fig. 2c).
Therefore, we decided to test it as a preventive anti-metas-
tasis vaccine. Immunization of the KLH conjugated mouse
epitope peptide, Epi-SP, produced easily detectible anti-
bodies in Balb/c mouse.
In order to test the possibility of reducing cancer metas-
tasis, the metastasis assay by tail vein injection was applied
after three immunizations in complete Freund’s adjuvant
and incomplete Freund’s adjuvant (Fig. 2d). At the time
point that mice were sacrificed, metastatic nodules on the
lungs were counted (Fig. 2e, f). Epi-SP caused a statistically
significant reduction in the numbers of metastasis nod-
ules, indicating that immunizing cancer self Prss14/ST14
antigens can interfere with cancer metastasis.
To exclude the possibility of nonspecific effects for
blocking metastasis by raised antibodies, Epi-SP se-
quence-scrambled peptide, Epi-Sc was selected (Fig. 2g
and h). When two antigens were tested in parallel with
the 4 T1 and 4 T1 EpiKD cells for the tail vein metastasis
assays with immunization, 4 out of 5 mice immunized
with the Epi-SP peptide exhibited clear abolition of me-
tastasis, while Epi-Sc failed to block metastasis (Fig. 2g).
The levels of reduction in metastasis by immunization
were similar to the levels of 4 T1 EpiKD cells. These data
showed that the Prss14/ST14 peptide reduces 4 T1 can-
cer metastasis in a sequence specific manner. Each
antiserum only bound to their specific antigen sequence
with high specificity (Fig. 2h), indicating there is no
cross reactivity between two antibodies.
To address the question of how the immunizing Epi-SP
peptide can reduce 4 T1 cancer metastasis, abilities of
transendothelial migration in the presence of mouse sera
were examined in vitro. 4 T1 cancer cells seeded onto the
confluent monolayer of MS1 endothelial cells migrated
less in the presence of the anti-Epi-SP sera (Fig. 2i). This
suggested that the antibodies induced with Epi-SP peptide
interfered with metastasis through blocking transendothe-
lial migration of the cancer cells.
Stable autocatalytic circular loop peptides can interfere
with E0771 metastasis efficiently
We attempted to raise specific monoclonal antibodies
against the Epi-SP sequence without success. These un-
successful trials led us to think that the epitope peptide
may not be stable enough for screening the high affinity
antibodies. Thus, we reinvestigated the structure models
by measuring the distance of the amino acids in order to
make a stable loop (Additional file 1: Figure S2). The
24mer peptide spanning from aa604 to aa627 showed
the closest ends covering the autoactivation loop region.
This region is highly conserved in three species (Fig. 3a).
There is only one amino acid difference between the hu-
man and two murine sequences. We added cysteine at
the C terminal in order to make the disulfide bond by
reduction (25mer). Structure modeling of the autoactiva-
tion loop based on the structure analyses of whole hu-
man and mouse protein derived from the crystal studies
revealed very similar structures while modeling of circu-
lar 25mer peptide sequences were comparable (Fig. 3b).
The first immunization of three KLH conjugated pep-
tides, mouse sequence derived Epi-SP and human de-
rived linear 24mer (Mat-Linear) and cysteine bonded
25mer loop (Mat-Loop) with Alum adjuvant, showed
significant reduction while scrambled Epi-Sc antigen did
not in C57BL/6 metastasis assay (Fig. 3c). When KLH
conjugated antigen was tested along with two adjuvants,
Alum and MF59, it was clear that Mat-Loop could re-
duce the numbers and total areas of the metastasis nod-
ules of E0771 cells in the lung (Fig. 3d, e). In addition,
the size and weight increase of the lung in a highly effi-
cient manner that exceeds adjuvant effects with statis-
tical significance. It appeared that antibodies generated
in these conditions were all IgG1 isotypes, suggesting
that the TH2 type response is dominating (Fig. 3f).
mAb3F3 shows specificity to human protein and cross-
reactivity to mouse Prss14/ST14 loop
From the successful metastasis blocking result obtained
in the preventive metastasis vaccine using 25mer circular
peptide, we developed the specific monoclonal antibody
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that can recognize the autoactivation loop structures to
block activation and thus, block protease activity. In
order to generate structure specific mAb directly against
the autocatalytic loop of Prss14/ST14, we tried the hy-
bridoma with circular Mat-Loop peptide as an antigen.







Fig. 2 Conjugated peptide antigen as a preventive metastasis cancer vaccine. (a) Location of antigen Epi-SP in whole protein. (b) The sequences
of mouse and human Epi-SP. (c) The Location of Epi-SP (red) in the structure model. (d) Immunization protocol. (e) The survival curves with
immunization. Mice were sacrificed on day 19 to assess metastasis. (f) Number of metastasis nodule with immunization (Left). The representative
images of metastasis (Right). (g) The levels of 4 T1 metastasis inhibition with immunization of Epi-SP are similar to the levels of 4 T1EpiKD. 4 T1C:
4 T1Con, 4 T1KD: 4 T1EpiKD. (h) Antibody specificity to Epi-SP and Epi-Sc. Antigens were immunized three times and antibodies were examined
by ELISA. SP: EPi-SP, Sc: EPi-Sc. (i) Antiserum from the immunized mice blocks transendothelial migration. Overall scheme of the experiment is
shown on the left, cells migrated through MS1 endothelial cells toward the opposite side are shown on the right. Average and standard error of
means are shown






Fig. 3 (See legend on next page.)
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regard to its binding specificity (Fig. 4). mAb3F3 binds
specifically to the Mat-Loop peptide sequence as shown in
the ELISA coated with BSA conjugated Mat-Loop, but
not with BSA alone (Fig. 4a). mAb3F3 binding to the BSA
conjugated Mat-Loop on the ELISA plate was competed
with Mat-Loop as well as Epi-Loop (Fig. 4b), revealing the
cross reactivity to human and mouse protein sequences.
The specific inhibitions were also tested in ELISA with
coating peptide antigen through the C-terminal end (data
not shown).
Sequencing mRNA from the hybridoma revealed
CDR1,2,3 regions forming antigen binding pockets in
both heavy and light chains (Table 1). Thereafter, the
structure of mAb3F3 Fab region was predicted based
on the amino acid sequences (Fig. 4c) and applied in
docking modeling (Fig. 4d). As shown, the antigenic
loop, taken from the whole protein model, fits nicely to
the antibody binding pocket. The CDRs of mAb3F3
covers the activation cleavage site (Fig. 4e). SPR sensor-
grams determined affinity of mAb3F3 against BSA con-
jugated peptide antigens (Additional file 1: Figure S3).
The mAb3F3 affinities against both human loop (Mat-
Loop) and mouse loop (Epi-Loop) peptides were at the
nanomole levels (human: KD = 5.333 × 10
− 9, mouse:
KD = 7.814 × 10
− 9) (Table 2). The linear form showed
two logs lower affinity while the scrambled sequence
showed no binding at all.
mAb3F3 shows the specificity to the native form of
Prss14/ST14 protein present in human and mouse breast
cancer cells
When the peptide antigen was used to raise monoclo-
nal antibody, an important issue was to see if
mAb3F3 could recognize the native protein structure.
Therefore, we tested whether mAb3F3 binds to
Prss14/ST14 expressed in cells. HEK293T cells were
transfected with full length human Prss14/ST14 (Mat)
and tested by immunoprecipitation (Fig. 4f and g). As
shown in the figures, simple western blotting revealed
four major different processed forms when the full
length construct was transfected into HEK293T cells,
mAb3F3 strongly immunoprecipitated two longer
bands, unprocessed and processed at aa149 (Fig. 4f).
When a construct consisting of recombinant EGFP
fused with Prss14/ST14 protein containing S805 mu-
tation, EGFP-S805A, was transfected, it was found in
the immunocomplex with mAb3F3 (Fig. 4g). The con-
trol transfection with EGFP did not show any detecti-
ble band. Then we verified that mAb3F3 bound to
endogenous Prss14/ST14 expressed in human MCF7
(Fig. 4h). mAb3F3 can also easily detect mouse pro-
tein of 4 T1 breast cancer cells (Fig. 4i). These results
suggested that mAb3F3 specifically binds to the
mouse and human native proteins. To further verify
that mAb3F3 can bind to native Prss14/ST14 in an-
other assay, we used flow cytometry (Fig. 4j and k).
mAb3F3 was able to detect Prss14/ST14 protein
expressed in the cells in a sequence specific competi-
tive manner. Sequence specificity was apparent since
binding can be competed away with only the peptide
of its own, not of the scrambled. Binding specificity
was also verified using two dimensional analysis with
CD8 protein expressing cells as a negative population.
mAb3F3 can detect PRSS14/ST14 expressed in various
cancer cell lines
We also investigated the possible usage of mAb3F3 as a
diagnostic tool. mAb3F3 was applied in immunocyto-
chemical staining on various cancer cell lines (Fig. 5).
Specific Prss14/ST14 staining in the cytoplasm, cell
contacts, and the membrane were detected in human
breast cancer cells, MCF7 and T47D (Fig. 5a and b).
There was no apparent background staining of the sec-
ondary reagent, and nuclear staining was found. Interest-
ingly, Prss14/ST14 staining was found only in the
subpopulation of MCF7 cells (Fig. 5a). An extended appli-
cation on other human and mouse cancer cell lines with
expression of Prss14/ST14 showed mAb3F3 can stain
membrane or cell contact areas of MDA-MB-453 triple
negative breast cancer, SNU216 and MKN45 human gas-
tric adenocarcinoma, PC3 human prostate cancer, OE19
human esophageal adenocarcinoma, and HCT116 human
colon carcinoma (Fig. 5c). In SNU216 cells, staining was
also clearly present in the cytoplasm. 427.1.86 mouse
thymoma cell and 4 T1 mouse breast cancer cell lines
were also stained very well (Fig. 5d). All the cell lines used
here were known to express Prss14/ST14 protein. There-
fore, mAb3F3 can be a new unique diagnostic reagent to
(See figure on previous page.)
Fig. 3 Circular autoactivation loop antigen modified to form stable structure worked as a preventive metastasis vaccine in C57BL/6 mouse. (a)
The amino acid sequence 604:627 of human Prss14/ST14 that contains an autoactivation cleavage site is well conserved. (b) The modeling of the
aa604:627 structures from human and mouse Prss14/ST14 whole protein models (left two panels). aa604:627 peptide does not retain the original
loop structure (Linear). A cysteine added to the 627th amino acid to form cysteine bond makes the loop structure (Loop). The activation cleavage
site is indicated with arrows. (c) Preventive metavaccine effects of various peptide antigen forms. 1 × 106 E0771 cells were injected via tail vein of
C57BL/6 mice after immunization of EP-SP, Mat-Loop, and Mat-Linear with Alum. (metastatic area/ whole area *100). (d) Metastasis inhibition of
SP, Loop peptides, and KLH carrier protein. E0771 cells (1 × 106) were injected via tail vein after immunization with MF59. The lung weight was
measured on the day of sacrifice. (E) The representative images of the metastasis. (f) The examination of antibodies (Left) and isotypes (Right)










Fig. 4 (See legend on next page.)
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detect an unactivated form of Prss14/ST14 protein with
the intact uncleaved activation loop structure.
mAb3F3 decreases cancer cell migration and metastasis
but does not effect on cell growth or cell death
The roles of mAb3F3 were first tested in vitro. Addition
of mAb3F3 hybridoma culture supernatant to 4 T1 cul-
ture reduced cell migration induced by wound healing in
a statistically significant way (Fig. 6a). Addition of puri-
fied mAb3F3 to MCF7 culture reduced cell migration in-
duced by serum gradient through transwell in a dose
dependent manner (Fig. 6b). In contrast, mAb5 that
binds to the denatured Prss14/ST14 did not reduce the
migration. Purified mAb3F3 did not affect MCF7 cell
growth (Fig. 6c) nor cell death when tested by cell cycle
analysis (Fig. 6d).
Next, tumor bearing MMTV-PyMT mice were
treated with mAb3F3 antibody or with taxol from 6
weeks of age (day 0). There were no significant differ-
ences found in the increase of primary tumor volume
among the three groups except small size decreases
in the mAb3F3 treated mice at day 11 (Fig. 6e and f).
However, metastasis in the lungs revealed significant
reduction of the number of tumor nodules at day 14
(Fig. 6g and h). These results indicated that mAb3F3
can inhibit cancer metastasis in the MMTV-PyMT
mouse model, but not tumor growth with our proto-
col applied. From these results, we concluded that
mAb3F3 is a promising candidate of preventive/thera-
peutic antibody to target metastasis.
Humanized mAb3F3 maintained specificity and reduced
cancer cell migration
In order to humanize mAb3F3, we engineered huAb3F3
by grafting murine CDRs onto its similar human germline
sequences (Additional file 1: Fig. 4). Prior to undertaking
the humanization of mAb3F3, a chimeric antibody
(ch3F3) was also constructed in which the entire mouse
mAb3F3 variable region was attached to human constant
regions. Purified antibody preparation located in a main
peak close to 100% of the total integrated peak area as
determined by size exclusion HPLC without significant
aggregation (data not shown). Humanized antibodies were
characterized for binding affinity using SPR-based assay
(Additional file 1: Figure S5). The binding affinity of
ch3F3, two humanized clones, huAb3F3–35 and
huAb3F3–37 measured were in the sub-nanomolar range.
Using two humanized clones huAb3F3–35 and
huAb3F3–37, we tested their abilities in the MCF7 cell
migration through transwell (Fig. 7a). The levels of cell
migration inhibition were clearly comparable to the parent
mAb3F3 (huAb3F3–35) or even better (huAb3F3–37) in
dose dependent fashion. A negative control monoclonal
antibody, mAb5, that recognized denatured protease do-
main did not reduce transwell migration.
To verify the specificity of the humanized clones, we ap-
plied flow cytometry using the HEK293TF cell line by trans-
fecting a protease activity mutant, MatS805A along with
EGFP. Negative population was transfected only with tdTo-
mato. As seen in Fig. 7b, huAb3F3–37 showed distinctly bet-
ter differences in the levels of staining with MatS805A cells,
suggesting cleaner specificity than huAb3F3–35 (Fig. 7b).
These results suggested that humanized antibody
huAb3F3–37 is a strong candidate to apply as a reagent tar-
geting breast cancer diagnosis and/or as a therapeutic reagent.
(See figure on previous page.)
Fig. 4 Production and characterization of mAb specific to autocatalytic loop. (a) mAb3F3 specifically binds to the autocatalytic loop. ELISA of
mAb3F3 binding to the BSA conjugated Mat-Loop, and not to BSA only. (b) Competition human (Mat-Loop) and mouse loop (Epi-Loop) peptides
to mAb3F3 binding on ELISA, coated with BSA conjugated human loop peptide. SC, scrambled sequence did not compete. (c) Modeling of
mAb3F3. Red: H-CDR1, Yellow: H-CDR2, Blue: H-CDR3, Green: L-CDR1, Purple: L-CDR2, Gray: L-CDR3. (d) Docking modeling of mAb3F3 to Mat-loop
peptides (lowest energy, − 238). Cyan: loop peptide. (e) Amino acids interacting with mAb3F3 in Mat-loop peptide were indicated as cyan. White
arrow indicates the activation cleavage site. (f-i) Immunoprecipitation and western blotting for testing specific interaction of mAb3F3 to native
Prss14/ST14 in cells. (f) Whole lysates of HEK293T cells transfected with full-length human Prss14 (Mat) and vector (Vec) were reacted with
mAb3F3. (g) Whole lysates of HEK293T cells transfected with EGFP-S805A and EGFP was immunoprecipitated with mAb3F3 (h)
Immunoprecipitation of MCF7. (i) Immunoprecipitation of 4 T1. (j) Flow cytometry of human Prss14/ST14 expressing HEK293T cells. Mat-Loop and
Epi-Sc were used for competition. (k) Flow cytometry with CHO-S cells transiently transfected with CD8 or full length Prss14/ST14
Table 1 Amino acid sequences of complementarity-





Total Length 112 113
Sequences of CDR1 RSSQSIVHSNGNTFLE GYTFSIYWLE
Sequences of CDR2 KVSNRFS EILPGSGNANYNEKFKG
Sequences of CDR3 FQGSHVPFT SGTD
Table 2 Kinetic measurement of mAb3F3 against various
peptides antigen using SPR
ka(1/Ms) kd(1/s) KD(M)
Mat-loop-BSA 6.414 × 105 0.003420 5.333 × 10−9
Epi-loop-BSA 4.131 × 105 0.003228 7.814 × 10−9
Mat-Linear 2.593 × 104 0.01052 4.057 × 10−7
Scrambled No binding
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Discussion
In this study, we showed that Prss14/ST14 is a critical
marker for breast cancer metastasis and a therapeutic tar-
get. Structural epitope peptide can prevent metastasis
when immunized prior to injection of metastatic breast
cancer and mAb directed to the activation loop of the pro-
tein can detect the native protein and inhibit metastasis.
As we are currently gathering more information on
the mechanism of metastasis, it now appears as a com-
plicated multistage and multipathway process [36, 37].
Either as a single cell dissemination or a collective tumor
cell migration, most tumor cells undergo EMT and ex-
travasation process after escaping hypoxia by angiogen-
esis to settle at distant sites. In addition, heterogeneous
cancer cells can escape from therapy to migrate out of
its original site. For targeting breast cancers, recent re-
views summarized the components and suggested key
pathways [38, 39]. We are confident that this research
will be a great addition to the list.
Prss14 as a therapeutic target against metastatic breast
cancer
We showed Prss14/ST14 is a strong prognosis marker for
highly mortal ER− breast cancer patients [8]. The survival
of ER− breast cancer patients with high expression level of
Prss14/ST14 is extremely poor while no death was apparent
with patients with low expression level. Prss14/ST14 is
valuable as a marker for poor survival of the post-surgery
esophageal cancer [40]. Using several immunocompetent
models, we verified that the importance of Prss14/ST14
A B
C D
Fig. 5 Immunofluorescence detection of Prss14/ST14 expression in various human and mouse cancer cells. (a) MCF7 breast cancer cell stained
with DAPI, actin, and mAb3F3 (b) T47D breast cancer cell stained with mAb3F3 and DAPI. (c) Various cancer cells stained with mAb3F3. MDA-MB-
453: human triple negative breast cancer cell line, SNU216: human gastric adenocarcinoma cell line, MKN45: human gastric cancer cell line, PC3:
human prostate cancer cell line, OE19: esophageal adenocarcinoma cell line, HCT116: human colon carcinoma, (d) 427.1.86: mouse thymoma cell
line, 4 T1: mouse breast cancer cell line. Bottom, Photoshop stylized presentation of staining pattern




Fig. 6 mAb3F3 can reduce cell migration and metastasis of MMTV-PyMT breast cancer. (a) Wound healing migration assay with 4 T1. mAb3F3
culture supernatant was added to the final concentration of 10%. (b) Transwell migration assay with MCF7. Dose response curves and
representative fields are at the bottom. mAb5: Solid line, mAb3F3: Dotted line. (c) 5 × 104 cells of MCF7 were seeded in 12 well plates. After 12 h,
MCF7 were treated with mAb3F3 or control. Number of cells were checked every 24 h. (d) Cell cycle analysis by Propidium Iodide staining. Same
numbers of MCF7 cells were seeded. (e) Growth curves of average tumor sizes from PBS, Taxol, and mAb3F3 injected PyMT mice. Arrows indicate
injection time points (days) of mAb3F3. (f) Tumor volumes of each group at day11. (g) Number of metastasis nodules at day14. (h) Representative
lung images of each group at the bottom
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roles in metastasis in breast cancer (Figs. 1, 2, 3 and 6). The
survival of mice orthotopically transplanted with 4 T1 or
E0771 breast cancer cells were significantly increased when
Prss14/ST14 was knocked-down. Prss14/ST14 functions
have more effect in metastasis than in the growth of the
primary tumors.
Despite the high mortality of patients with malignant
tumors, there are no active preventive strategy on future
metastasis after the primary tumor mass has been re-
moved. Either dietary or adjuvant therapy are currently
the most applicable options, probably because there is
no usable target for blocking metastasis. There has been
an earlier attempt to reduce metastasis using CD44 [41],
uPA [42], or AECHL-1 as targets [43]. Now, we strongly
believe that Prss14/ST14 is as good as, if not better, a
candidate for modulating metastasis. Prss14/ST14 is in-
volved in all the important processes of metastasis,
angiogenesis, EMT, cell invasion into matrix, cell migra-
tion, and transendothelial migration since it digests
matrix proteins and activates many metastatic pathways.
More importantly, it can activate itself like a master
switch. If we block the function of Prss14 as an active
protease at the level of activation, we will be able to
block the entire downstream events.
Epitopes can behave as a preventive metastasis vaccine
To our surprise, the highly conserved autoactivation loop
sequence (SP) and the modified peptide to maintain the
loop structure to form a disulfide bond (Loop) (Fig. 2 and
Additional file 1: Figure S2) behaved as efficient epitopes
(Figs. 2, 3 and 6). The KLH conjugated epitopes with vari-
ous adjuvants worked as preventive metastasis vaccines in
two mouse metastatic breast cancer models (Fig. 2 and
Fig. 3). In contrast to our initial concern of Prss14/ST14
being self-antigen, present in thymic epithelium, which in-
duces self-tolerance [44, 45], all the mice generated suffi-
ciently detectible Th2 type antibodies (Fig. 2h and Fig. 3f).
Epi-SP, Mat-Linear, and Mat-Loop epitopes showed
potential to be preventive metastasis vaccines (Fig. 2 and
Fig. 3). They were able to raise high titer antibodies and
eliminated metastasis nodules. Prevention of metastasis
with immunization of these antigens was sequence spe-
cific. The reduction of metastasis was as efficient as the
knocking down of Prss14/ST14, and better than the sole
A B
Fig. 7 huAb3F3 clones inhibit cell migration and specifically bind to uncleaved protein. (a) Transwell migration assay with MCF7. 5 × 104 cells
were seeded on the upper chamber and incubated with antibody without serum. After 4 h, the lower chamber was filled with media with serum
for 24 h. mAb5: Solid black line, m3F3 (mAb3F3): Solid red line, 3F3–35 (huAb3F3–35): Dotted orange line, 3F3–37 (huAb3F3–37): Dotted green
line. (b) Flow cytometric analysis of HEK293TF cells co-transfected with either EGFP and matriptaseS805A or with tdTomato using huAb3F3 Ab
clones. Blue population: tdTomato+, Red population: GFP+
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effect of the adjuvant. The mechanism of prevention of
metastasis is at least in part by reducing the ability of
transendothelial cell migration as shown in Fig. 2I. How-
ever, more detail mode of actions will require extensive
studies.
mAb3F3 as a new immunologic agent targeting
metastasis
mAb3F3 that recognize the autoactivation loop of
Prss14/ST14 was investigated for its specificity by several
assays (Fig. 4). In ELISA, mAb3F3 specifically binds to
the epitopes, either conjugated with BSA or C-terminal
linked peptide which can maintain the structure of pep-
tide. mAb3F3 clearly recognized the native forms of
Prss14/ST14 expressed in cells detected by immunopre-
cipitation and by flow cytometry. The bindings to the
native protein structure were competed with only the
same sequences. The affinities to the human and mouse
epitopes are within the range of nanomoles (Table. 2
and Additional file 1: Figure S3).
Because epitope structure is destroyed by cleavage
within the autoactivation loop sequence, mAb3F3 can
only bind the inactive form. It is going to be useful to
distinguish the inactive form from the activated form.
mAb3F3 can stain various cultured cancer cells (Fig. 5),
suggesting its value as a diagnostic tool as well.
mAb3F3 clearly reduced in vitro cell migration, trans-
well assays, and metastasis in MMTV-PyMT mice while
it did not interfere with cell growth, cell death, or cell
cycle (Fig. 6). The effects of mAb3F3 on tumor metasta-
sis were better than taxol treatment, suggesting that a
combination of taxol and mAb3F3 may yield better in-
hibition. One humanized antibody huAb3F3–37 main-
tained a high level of specificity and as good as, if not
better, in vitro effect on cell migration (Fig. 7a). There-
fore, mAb3F3 and huAb3F3–37 are good candidates of
therapeutic antibodies to the metastatic breast cancers
and can be used as a component in combination ther-
apy. If antibody mediated endocytosis is sufficient, these
reagents can also be good lead materials as antibody
drug conjugates for targeting the removal of early cancer
cells with unactivated Prss14/ST14 protease on the
surface.
Conclusions
Our study demonstrates that Prss14/ST14 is an import-
ant target for metastasis modulation, an epitope derived
from the structure, specifically the autoactivation loop,
can be useful as a preventive a metastasis vaccine. Our
newly developed mAb3F3 and huAb3F3 can recognize
the structure and sequence specific epitope of the auto-
activation loop, and may function as a therapeutic anti-
body targeting metastasis modulation.
Additional files
Additional file 1: Figure S1. Prss14/ST14 knockdown in E0771 cell line.
Figure S2. Designing antigen to maintain stable autoactivation loop
structure. Figure S3. SPR sensorgrams show binding of human and mouse
loop to mAb3F3. Figure S4. Amino acid sequence of humanized antibodies
aligned with human germlines and mouse antibody. Figure S5. huAb3F3
antibodies showed a similar level of antigen binding capacity as the
chimeric antibody. (PPTX 1022 kb)
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